Clinical Trial Detail

NCT ID NCT02003092
Title RX-5902 Treatment of Subjects With Solid Tumors
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements yes
Sponsors Rexahn Pharmaceuticals, Inc.
Indications

triple-receptor negative breast cancer

Therapies

RX-5902

Age Groups: adult senior

Additional content available in CKB BOOST